Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort

References

• LavanchyDThe global burden of hepatitis CLiver Int200929 Suppl 1 74 81
   Web of Science ®Google Scholar
• PerzJFArmstrongGLFarringtonLAHutinYJBellBPThe contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwideJ Hepatol2006454 529 53816879891
   PubMed Web of Science ®Google Scholar
• CarboneMLenciIBaiocchiLPrevention of hepatitis C recurrence after liver transplantation: an updateWorld J Gastrointest Pharmacol Ther201234 36 4822966482
   PubMedGoogle Scholar
• AkamatsuNSugawaraYLiver transplantation and hepatitis CInt J Hepatol20122012 68613522900194
   PubMedGoogle Scholar
• Garcia-RetortilloMFornsXFeliuAHepatitis C virus kinetics during and immediately after liver transplantationHepatology2002353 680 68711870384
   PubMed Web of Science ®Google Scholar
• BerenguerMPrietoMSan JuanFContribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipientsHepatology2002361 202 21012085366
   PubMed Web of Science ®Google Scholar
• BerenguerMNatural history of recurrent hepatitis CLiver Transpl2002810 Suppl 1 S14 S1812362293
   PubMed Web of Science ®Google Scholar
• BerenguerMPrietoMRayonJMNatural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantationHepatology2000324 Pt 1 852 85811003634
   PubMed Web of Science ®Google Scholar
• FormanLMLewisJDBerlinJAFeldmanHILuceyMRThe association between hepatitis C infection and survival after orthotopic liver transplantationGastroenterology20021224 889 89611910340
   PubMed Web of Science ®Google Scholar
• GhabrilMDicksonRWiesnerRImproving outcomes of liver retransplantation: an analysis of trends and the impact of hepatitis C infectionAm J Transplant200882 404 41118211509
   PubMed Web of Science ®Google Scholar
• RocheBSamuelDRisk factors for hepatitis C recurrence after liver transplantationJ Viral Hepat200714 Suppl 1 89 96
   Web of Science ®Google Scholar
• BerenguerMPalauAAguileraVRayonJMJuanFSPrietoMClinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantationAm J Transplant200883 679 68718294165
   PubMed Web of Science ®Google Scholar
• LawitzELalezariJPHassaneinTSofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialLancet Infect Dis2013135 401 40823499158
   PubMed Web of Science ®Google Scholar
• LawitzESulkowskiMSGhalibRSimeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyLancet20143849956 1756 176525078309
   PubMed Web of Science ®Google Scholar
• BurraPZanettoAFilling the gap between clinical trials and real life in the treatment of severe HCV recurrence after liver transplantationTranspl Int2017303 239 24228102906
   PubMed Web of Science ®Google Scholar
• HerzerKWelzelTMSpenglerUReal-world experience with daclatasvir plus sofosbuvir ±ribavirin for post-liver transplant HCV recurrence and severe liver diseaseTranspl Int2016303 243 255
   Web of Science ®Google Scholar
• CiesekSProskeVOttoBEfficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantationTranspl Infect Dis2016183 326 33226988272
   PubMed Web of Science ®Google Scholar
• MariaCMichaelSSusanneCCatarinaSOlaWINF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse – a Swedish real life experienceScand J Gastroenterol2017525 585 58828270038
   PubMed Web of Science ®Google Scholar
• BerenguerMAguileraVPrietoMWorse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosisLiver Transpl2009157 738 74619562707
   PubMed Web of Science ®Google Scholar
• WiesnerRHSorrellMVillamilFInternational Liver Transplantation Society Expert PanelReport of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis CLiver Transpl2003911 S1 S9
   Web of Science ®Google Scholar
• BerenguerMPalauAFernandezAEfficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis CLiver Transpl2006127 1067 107616622844
   PubMed Web of Science ®Google Scholar
• KornbergAKupperBTannapfelAThrumKBarthelESettmacherUAntiviral treatment withdrawal in viremic HCV-positive liver transplant patients: impact on viral loads, allograft function and morphologyLiver Int2006267 811 81616911463
   PubMed Web of Science ®Google Scholar
• GhanyMGNelsonDRStraderDBThomasDLSeeffLBAmerican Association for Study of Liver DAn update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology2011544 1433 144421898493
   PubMed Web of Science ®Google Scholar
• ZimmermannTBeckebaumSBergCExpert recommendations: hepatitis C and transplantationZ Gastroenterol2016547 665 684 German27429106
   PubMed Web of Science ®Google Scholar
• European Association for Study of LiverEASL recommendations on treatment of hepatitis C 2014J Hepatol2014612 373 39524818984
   PubMed Web of Science ®Google Scholar
• European Association for Study of LiverEASL recommendations on treatment of hepatitis C 2015J Hepatol2015631 199 23625911336
   PubMed Web of Science ®Google Scholar
• CarrionJANavasaMGarcia-RetortilloMEfficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled studyGastroenterology20071325 1746 175617484872
   PubMed Web of Science ®Google Scholar
• PrietoMBerenguerMRayonJMHigh incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodesHepatology1999291 250 2569862874
   PubMed Web of Science ®Google Scholar
• ZimmermannTOttoCHoppe-LotichiusMRisk factors in patients with rapid recurrent hepatitis C virus-related cirrhosis within 1 year after liver transplantationTransplant Proc2009416 2549 255619715972
   PubMed Web of Science ®Google Scholar
• WillemseSBRazavi-ShearerDZuureFRThe estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigmsNeth J Med2015739 417 43126582807
   PubMed Web of Science ®Google Scholar
• CharltonMEversonGTFlammSLLedipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver diseaseGastroenterology20151493 649 65925985734
   PubMed Web of Science ®Google Scholar
• CharltonMGaneEMannsMPSofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantationGastroenterology20151481 108 11725304641
   PubMed Web of Science ®Google Scholar
• MannsMFornsXSamuelDG02: Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the prospective solar 2 trialJ Hepatol201562Suppl 2 S187 S188
   Web of Science ®Google Scholar
• SaxenaVTerraultNCurrent management of hepatitis C virus: regimens for peri-liver transplant patientsClin Liver Dis2015194 669 688 vi26466655
   PubMed Web of Science ®Google Scholar
• BaconBRGordonSCLawitzEHCV RESPOND-2 InvestigatorsBoceprevir for previously treated chronic HCV genotype 1 infectionN Engl J Med201136413 1207 121721449784
   PubMed Web of Science ®Google Scholar
• ZeuzemSAndreonePPolSREALIZE Study TeamTelaprevir for retreatment of HCV infectionN Engl J Med201136425 2417 242821696308
   PubMed Web of Science ®Google Scholar
• ZeuzemSMensaFJConcordance between SVR12and SVR24 in genotype 1 HCV patients receiving interferon-free treatment in the SOUND-C2 studyHepatology2013584 1516
   PubMed Web of Science ®Google Scholar
• CoillyAFougerou-LeurentCde LedinghenVANRS C023 CUPILT Study GroupMulticentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence – the ANRS CUPILT studyJ Hepatol2016654 711 71827262758
   PubMed Web of Science ®Google Scholar
• DumortierJLeroyVDuvouxCSofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantationLiver Transpl20162210 1367 137827348086
   PubMed Web of Science ®Google Scholar
• WelzelTMNelsonDRMorelliGHCV-TARGET Study GroupEffectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET studyGut2016 pii: gutjnl-2016-311609
   Web of Science ®Google Scholar
• KwoPYMantryPSCoakleyEAn interferon-free antiviral regimen for HCV after liver transplantationN Engl J Med201437125 2375 238225386767
   PubMed Web of Science ®Google Scholar
• PungpapongSAqelBLeiseMMulticenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplantHepatology2015616 1880 188625722203
   PubMed Web of Science ®Google Scholar
• RothDNelsonDRBruchfeldAGrazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyLancet201538610003 p1537 p1545
   PubMed Web of Science ®Google Scholar